Osimertinib in EGFR-Mutated Lung Cancer. Reply

N Engl J Med. 2021 Feb 18;384(7):675-676. doi: 10.1056/NEJMc2033951.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Acrylamides*
  • Aniline Compounds
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics

Substances

  • Acrylamides
  • Aniline Compounds
  • osimertinib
  • EGFR protein, human
  • ErbB Receptors